Jonathan T. Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan T. Pham has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Amanda M. Johnson
Mayo Clinic
1 shared publication - Andres Acosta
Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Edward Vincent Loftus
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN
1 shared publication - Linda Anne Feagins
Division of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, TX
1 shared publication - Wissam Ghusn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Vedolizumab as a Second Line Biologic for Cronkhite Canada Syndrome and an Approach Toward Disease Monitoring
A 62-year-old woman was diagnosed with Cronkhite-Canada Syndrome, presenting with classic clinical symptoms and endoscopic findings. She initially responded to infliximab (IFX) with symptomatic improvement, normalized calprotectin, and minimal disease activity on endoscopy for 3 years. Despite IFX trough levels appropriate for inflammatory bowel disease goals and no IFX antibodies, she subsequently lost response and had recurrence of symptoms and disease activity. She started on a course of corticosteroids, discontinued IFX, and transitioned to vedolizumab with standard induction and maintenance dose every 8 weeks, achieving clinical remission and near complete endoscopic remission.
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Open AccessVedolizumab as a Second Line Biologic for Cronkhite Canada Syndrome and an Approach Toward Disease Monitoring
A 62-year-old woman was diagnosed with Cronkhite-Canada Syndrome, presenting with classic clinical symptoms and endoscopic findings. She initially responded to infliximab (IFX) with symptomatic improvement, normalized calprotectin, and minimal disease activity on endoscopy for 3 years. Despite IFX trough levels appropriate for inflammatory bowel disease goals and no IFX antibodies, she subsequently lost response and had recurrence of symptoms and disease activity. She started on a course of corticosteroids, discontinued IFX, and transitioned to vedolizumab with standard induction and maintenance dose every 8 weeks, achieving clinical remission and near complete endoscopic remission.
- 23 September 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (6) , 1197-1200
Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease
INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of −6.9 ± 8.3 and −8.1 ± 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
- 23 September 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (6) , 1197-1200
Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease
INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of −6.9 ± 8.3 and −8.1 ± 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.